ASN 001

Drug Profile

ASN 001

Alternative Names: ASN001

Latest Information Update: 17 Jul 2017

Price : $50

At a glance

  • Originator Asana BioSciences
  • Class Antineoplastics
  • Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 02 Jun 2017 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Prostate cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Feb 2015 ASN 001 is available for licensing as of 02 Feb 2015. http://www.asanabiosciences.com/
  • 02 Feb 2015 Asana Biosciences plans a phase I/II trial for Prostate cancer (Late-stage disease, Metastatic disease) in USA (NCT02349139)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top